Worcester biomedical firm raises $3M for development of pelvic treatments
Photo | Timothy Doyle
UMass Chan Medical School is home to Juniper Biomedical.
Juniper Biomedical has raised $3 million in capital from a seed funding round, as well as the National Institutes of Health, to support its advancements in neuromodulation technology.
Juniper Biomedical, composed of five employees, works to develop therapies to treat pelvic health conditions such as urinary incontinence, bowel incontinence, pelvic pain, sexual dysfunction, and pelvic floor disorders, according to a Tuesday release from Juniper.
The medical device company has completed a $2-million seed funding round led by Auroral Holdings, a medtech-focused family office in Worcester, with participation from Atma Capital in Florida, Hub Angels Investment Group in Boston, Beacon Angels in Boston, and other private investors.
"We believe that Juniper Biomedical has tremendous potential for growth and disruption in pelvic health in the historically underserved patient populations," Larry Derose, founder of Auroral Holdings, said in the release. “We are excited to partner with the company and look forward to supporting the team’s vision and innovation."
Juniper Biomedical was awarded $1 million through the NIH Common Fund for winning its Stimulating Peripheral Activity to Relieve Conditions Neuromod Prize, a competition designed to expedite the development of targeted neuromodulation therapies, according to the release.
The newly sustained funds will allow Juniper Biomedical to complete development and commercialization milestones for its neuromodulation technology.
"Our team will leverage these new funds to accelerate the development of transformative solutions for multiple care gaps in pelvic health,” David Constantine, co-founder and CEO of Juniper Biomedical, said in the release.
WBJ Web Partners
Most Recent
Most Recent
0 Comments